CeQur CEO Robert Farra transitions to chief technology officer, succeeded by Bradley Paddock

CeQur announced Wednesday the appointment of Bradley Paddock as CEO, effective immediately, replacing Robert Farra, who has held the position since November 2016 and will move into a new role as chief technology officer.

According to CeQur, Paddock most recently served as global president of Stryker's global spine division. Prior to this, Paddock worked as a sales representative at Johnson & Johnson's Ethicon Endo-Surgery, before joining Kyphon in 1999. After Medtronic acquired Kyphon, Paddock joined Bausch + Lomb as vice president of global sales and marketing.

Eric Milledge, CeQur's executive chairman, noted that "the sales increase [Paddock] drove at Kyphon resulted in an acquisition by Medtronic for $4.2 billion. We believe that this accomplishment, in addition to his impressive history developing commercial organisations, will ensure that CeQur is best placed for rapid development ahead of our launch of the PAQ MEAL insulin delivery device in early 2020."

According to CeQur, PAQ MEAL, which was formerly known as OneTouch Via and Calibra Finesse, provides on-demand mealtime insulin delivery, while PAQ TOTAL, which was formerly known as the PAQ insulin delivery device, delivers both basal and on-demand mealtime insulin. The company gained PAQ MEAL last year after acquiring certain assets from Johnson & Johnson's diabetes care company Calibra Medical for an undisclosed sum. At the time, CeQur indicated that the device, which is FDA-approved for use by adults with diabetes who require insulin, will be launched in mid-2019.

Did you like this article?